

University of Dundee

**Examination of the clinical factors associated with attendance at emergency departments for chronic pain management and the cost of treatment relative to that of other significant medical conditions**

Higgins, Cassie; Smith, Blair H.; Colvin, Lesley

*Published in:*  
Pain

*DOI:*  
[10.1097/j.pain.0000000000002098](https://doi.org/10.1097/j.pain.0000000000002098)

*Publication date:*  
2021

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

Higgins, C., Smith, B. H., & Colvin, L. (2021). Examination of the clinical factors associated with attendance at emergency departments for chronic pain management and the cost of treatment relative to that of other significant medical conditions. *Pain*, 162(3), 886-894. <https://doi.org/10.1097/j.pain.0000000000002098>

**General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# PAIN

## Examination of the clinical factors associated with attendance at emergency departments for chronic pain management and the cost of treatment relative to that of other significant medical conditions

--Manuscript Draft--

Manuscript Number:	PAIN-D-20-00763R1
Full Title:	Examination of the clinical factors associated with attendance at emergency departments for chronic pain management and the cost of treatment relative to that of other significant medical conditions
Article Type:	Research Paper
Keywords:	chronic pain; painful musculoskeletal conditions; Emergency Department; odds ratios; total costs; epidemiology
Corresponding Author:	Cassie Higgins, Ph.D. University of Dundee School of Medicine Dundee, UNITED KINGDOM
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Dundee School of Medicine
Corresponding Author's Secondary Institution:	
First Author:	Cassie Higgins, Ph.D.
First Author Secondary Information:	
Order of Authors:	Cassie Higgins, Ph.D.
	Blair H Smith, PhD
	Lesley Colvin, PhD
Additional Information:	
Question	Response
Have you posted this manuscript on a preprint server (e.g., arXiv.org, BioXriv, PeerJ Preprints)?	No

**ABSTRACT**

Little is known about risk factors for emergency department (ED) attendance for chronic pain (CP) management and the relative service burden. We examined emergency department (ED) utilisation in patients with chronic pain (CP), identified risk factors associated with attendance for chronic musculoskeletal pain (CMP) and estimated the comparative cost of treatment. The study cohort comprised a random sample of 3,700 adults from the general population in Tayside, Scotland. Linked regional extracts, spanning a 12-month period, were obtained from national registers, providing information on ED attendances, community-dispensed prescribing and outpatient clinic attendances. The NHS Scotland Cost Book was used to ascertain the current average cost of an ED attendance (£130; ~\$167).

All-cause ED attendance was higher in those with CP (68.5%; n=252) than without (29.3%; n=967). In the entire cohort, more patients attended the ED for the treatment of CMP than for any other medical condition (n=119; 32.3% of those with CP). Risk factors for ED attendance for CMP were: recent analgesic dose decreases (OR=4.55); and transitioning from opioid to non-opioid analgesics (OR=5.08). Characteristics protective of ED attendance for CMP were: being in receipt of strong opioids (OR=0.21); transitioning from non-opioid to opioid analgesics (OR=0.25); recent analgesic dose increases (OR=0.24); and being prescribed tricyclic antidepressants (OR=0.10), benzodiazepines (OR=0.46) or hypnotics (OR=0.45). CMP was one of the most expensive conditions to treat (£17,680 (~\$22,668) per annum), conferring a substantial burden on ED services. Improved understanding of the risk/protective factors could inform healthcare redesign to reduce avoidable ED attendances for CMP management.

Full title: Examination of the clinical factors associated with attendance at emergency departments for chronic pain management and the cost of treatment relative to that of other significant medical conditions

Running head: Chronic pain in emergency departments

Authors: Cassie Higgins<sup>1</sup>, Blair H Smith<sup>1</sup>, Lesley Colvin<sup>1</sup>

<sup>1</sup> Division of Population Health and Genomics, School of Medicine, Ninewells Hospital, University of Dundee

Corresponding author: Cassie Higgins, Division of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital & Medical School, Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF. [c.z.higgins@dundee.ac.uk](mailto:c.z.higgins@dundee.ac.uk)

Number of text pages (including pages containing figures and tables): 36

Number of figures: 4

Number of tables: 2

Keywords: chronic pain; painful musculoskeletal conditions; emergency department; odds ratios; total costs; epidemiology.

# **Examination of the clinical factors associated with attendance at emergency departments for chronic pain management and the cost of treatment relative to that of other significant medical conditions**

## **INTRODUCTION**

Emergency departments (EDs) internationally are under constant pressure to meet increasing demand [711,2431,2434,2738,2839,3449,3752]. A proportion of patients may represent potentially avoidable demand, such as some of those attending for chronic pain (CP) management. Indeed, many ED attendances for chronic diseases are reported to be preventable [5979]. Furthermore, the ED is not considered to be an appropriate setting for the management of CP [24,5270,6481,6282], and ED staff feel undertrained in treating this problem [85]. In order to better manage health services and treat patients more effectively, it is important to quantify the scale of this issue and understand the risk factors associated with ED attendance for the management of CP.

CP is defined as pain that persists beyond that of normal tissue healing time, usually considered to be 3 months [2940]. A systematic review of UK prevalence studies of CP [4625] reported a pooled prevalence estimate of 43.5% (95% CI 38.4% - 48.6%). CP ‘flare-ups’ are common, reported to occur in up to three quarters of patients with chronic non-cancer pain (CNCP) [4462]. CP accounts for 10-16% of all ED attendances in the USA [36,5270] with some individuals being heavily reliant on emergency service resources [5371,6481]. However, comparative UK figures are not currently available. Effective community-based pain management, with continuity of care, may help to reduce the pressure on emergency services whilst providing more stable pain management for patients. Indeed, a number of systematic reviews have reported the effectiveness of self-management techniques [4116], community-based strategies [3853] and work-based interventions [4158].

Very few studies have examined ED attendance for the management of CP. The precise nature of data collection in EDs in Scotland does not currently allow identification of all patients attending for CP management. Surrogate measures may potentially be used, such as recording of attendance for painful musculoskeletal conditions (excluding injury) among those identified with CP. The Global Burden of Disease (GBD) 2017 Study showed that painful musculoskeletal conditions are the highest contributor to global disability and that low back pain has remained the single leading cause of disability since the first GBD Study in 1990 [2333]. Indeed, one in two adult Americans are reported to live with a painful musculoskeletal condition, a prevalence comparable to that of cardiovascular and chronic respiratory diseases combined, totalling a cost of \$213 billion in 2011, or 1.4% of gross domestic product [5472]. Painful musculoskeletal conditions are reported to consume almost a tenth of the UK's National Health Service (NHS) budget, making this one of the most expensive specialties, after psychiatric disorders and cardiac disease [4563]. The present study aimed to:

- 1) Quantify the proportion of those identified with CP who attended the ED for any reason within a 12-month period and, specifically, those who attended for the treatment of CMP;
- 2) Characterise prescribed analgesic treatment in those identified with CP who attended the ED for any reason compared with those with chronic pain who did not attend the ED;
- 3) Identify the clinical factors associated with ED attendance for CMP;
- 4) Estimate ED resource utilisation associated with CP management compared with other significant medical conditions.

## METHODS

### *Participants and setting*

The study cohort comprised a random sample of 3,700 adults from the general population in the NHS Tayside Health Board area, drawn from the 2014 database of all individuals registered with a general practitioner (GP) in NHS Tayside. Each individual registered with a GP (>95% of the UK population) is assigned an NHS Community Health Index (CHI) number, a unique personal identifier that is contained within the medical records associated with all NHS events. This identifier was used to achieve record linkage and pseudo-anonymisation, as described below. The sample was generated by Health Informatics Centre (HIC) Services, Farr Institute, University of Dundee, using algorithms based on random number generation. All Scottish NHS services, including general practitioner services, are delivered free at the point of contact to all patients, and this includes the dispensing of prescribed medication.

### ***Data sources***

Regional data extracts were obtained from several national Scottish health registers, which are held by the Information Services Division (ISD) of National Services Scotland (NSS) and were accessed by HIC Services. The Accident & Emergency Datamart provides a record of all ED attendances and contains information on admission, diagnoses, treatment and discharge. The Prescribing Information System (PIS) is a dataset that contains information on the drugs, dosages and instructions for all community-dispensed prescriptions. The Scottish Morbidity Register (SMR) 00 contains a record of all NHS outpatient clinic attendances by specialty. The SMR06 is a register of all patients diagnosed with malignant disease. Demographic data were provided by HIC Services, from the NHS CHI dataset. These data comprised: gender; age; socioeconomic status using the Scottish Index of Multiple Deprivation (SIMD) quintiles (<https://www.gov.scot/collections/scottish-index-of-multiple-deprivation-2020/>); and urban-rural habitation using the Scottish Executive Urban Rural

Classification (SEUR; <https://www.gov.scot/publications/scottish-executive-urban-rural-classification-2005-2006/pages/8/>). In accordance with SIMD recommendations, quintiles 1-2 were used to indicate relative socioeconomic deprivation and quintiles 3-5 were used to indicate relative socioeconomic affluence. Scottish Health Service Costs (commonly referred to as the ‘Cost Book’) was used to ascertain the average cost of each ED attendance, which falls at £130 (~\$167). This unit cost is consistent with the unit cost used in previous UK-based studies, accounting for inflation [14,21,24,26,59]. Whilst the data used in the present study were collected in 2014, most recently-published Cost Book prices were used in calculating ED costs for each participant to allow a current understanding of the findings presented here. The most recent Cost Book (2017) for each specialty can be found at <http://www.isdscotland.org/Health-Topics/Finance/Costs/A-Z-Index/>, where ED costs by health board can be found in Table R044X.

### ***Procedure***

Data were extracted from each of the datasets spanning a 12-month period for each participant (i.e. the 2014 calendar year). All data were linked electronically within a secure virtual environment and anonymised prior to release to the research team via a Scottish Government-certified *Safe Haven* (Health Informatics Centre (HIC) Services, University of Dundee).

We used prescribing records to identify people likely to have chronic pain. Participants were identified as having ‘chronic pain’ if they had been in receipt of prescription analgesics for at least three consecutive months during the observation period. Participants identified as having ‘acute pain’ (receipt of analgesic treatment for less than three consecutive months within the observation period) were excluded from the present study. Within the PIS prescribing dataset there is a fully-completed field containing British



National Formulary (BNF) codes ([http://gmmmg.nhs.uk/html/formulary\\_bnf\\_chapters.html](http://gmmmg.nhs.uk/html/formulary_bnf_chapters.html)) used to indicate intention to treat, and these codes were used to identify participants who had been in receipt of analgesic prescriptions. This field was used to ensure that the therapeutic indication was ascertained for medication that could be used for multiple purposes; for example, the use of antidepressants or anticonvulsants in the treatment of pain. Individuals were included in the study where analgesia was indicated as the therapeutic intention for prescribing, and individuals were excluded where the indicated therapeutic intention was other than analgesia. The BNF codes used to identify participants with chronic pain are shown in the supplementary digital content (*Table S1*).

Malignant disease was identified through inclusion within the SMR06 and/or attendance at outpatient palliative care services (SMR00). The presence of opioid dependence was identified using BNF codes in the prescribing dataset (4.10.3 Opioid dependence). BNF codes in the prescribing dataset were also used to identify unipolar mood disorders (4.3 Antidepressant drugs), bipolar disorder (4.2.3 Drugs for mania and hypomania), anxiety disorders (4.1.2 Anxiolytics), sleep disorders (4.1.1 Hypnotics) and psychotic disorders (4.2.1 Antipsychotic drugs and 4.2.2 Antipsychotic depot injections). The receipt of pain treatment in secondary care was identified using the SMR00 (treatment at specialist pain services). However, it is important to note that chronic pain may be managed in other specialist settings (such as rheumatology), but it does indicate the use of secondary care pain services. The data did not permit the identification of non-pharmaceutical interventions for the treatment of pain.

Reasons for attendance at the ED were ascertained using the 'Diagnosis Code' field contained within the ED dataset. These data are recorded, at the time of attendance, as high-level codes, indicating the specialty of the presenting complaint. Data were extracted for some of the main significant clinical conditions: CMP ('12 musculoskeletal, excluding

injury'); cardiovascular disease ('03 cardiovascular'); respiratory disease ('17 respiratory'); gastrointestinal disorders ('08 gastrointestinal'); endocrine/metabolic disorders ('06 endocrine/metabolic'); substance use disorder ('02 alcohol and/or substance use problems'); and psychiatric disorders ('16 psychiatry'). There was no diagnostic code that would cover all chronic pain.

Equianalgesic computations were made only for opioid medication. Morphine-equivalent doses were established using an online equianalgesic calculator based on the American Pain Society guidelines and critical review papers focusing on the issue of equianalgesic dosing (<http://clincalc.com/opioids/>). The morphine-equivalent dose for each of the opioid medications from the present study is reported in the supplementary digital content (*Tables S2 and S3*).

'Strong' and 'weak' opioids were identified using the Analgesic Ladder compiled by the World Health Organization (WHO). Overall dose increases and decreases were identified by calculating each participant's mean dose during the first 3 months of the 12-month observation period and comparing that value with the mean of the final 9 months. A transition from opioid to non-opioid analgesics, and vice versa, was indicated where the cessation or initiation of opioid analgesic treatment occurred at any point during the observation period. No participants transitioned twice during this time, so the groups were mutually exclusive.

The data were hosted, linked and pseudo-anonymised within HIC Services. Since each of the datasets included in the present study comprised data pertaining to NHS events, all datasets included NHS CHI numbers for all individuals present in these datasets. HIC Services used the CHI numbers from the study sample (obtained from the CHI dataset) to identify all relevant individuals and extract all relevant data from the health datasets included in the present study. ~~Data were linked for each participant using the NHS CHI number.~~

Following linkage and the extraction of all relevant data, CHI numbers were replaced by proxy CHI (proCHI) numbers in the final release, with the key being retained securely within HIC Services. The research team was then able to track events for individuals across all data extracts using the pseudo-anonymised proCHI identifier. Data were analysed within the HIC Safe Haven, which was accessed via a secure web link, and outputs were scrutinised to ensure data security prior to release to the research team.

### *Statistical considerations*

Data were analysed using the Statistical Package for Social Sciences (SPSS; v22). The chi square test was used in the analysis of categorical dependent variables by categorical independent variables. Statistical findings were reported as chi-square value and degrees of freedom ( $\chi^2(df)$ ), probability value ( $p$ ) and effect size, Pearson's Phi or Cramer's V ( $\omega$ ). Pearson's Phi was used to assess the effect size in 2x2 contingency tables and Cramer's V was used where there were more than two levels in independent variables. Descriptive summary data were presented as number of participants ( $n$ ) and percentage of group (%).

Univariate analysis of variance (ANOVA) was used to assess continuous dependent variables by categorical independent variables. Statistical findings of the univariate ANOVA were reported as F value, between-subjects degrees of freedom and within-subjects degrees of freedom ( $F(\text{between-subjects df, within-subjects df})$ ), probability value ( $p$ ) and effect size, partial eta squared ( $\eta_p^2$ ). Descriptive summary data were presented as mean value ( $\bar{x}$ ) and standard deviation around the mean ( $\sigma$ ).

Binary logistic regression was used to assess the independent predictive capacity of categorical and continuous predictor variables on binary target variables. Tables show unadjusted odds ratio (OR), adjusted odds ratio ( $OR^{adj}$ ), and 95% confidence interval (95% CI).

## ***Ethical approval***

Ethical approval was not specifically required for the present study, since all data were pseudo-anonymised and accessed via a national Safe Haven; however, a favourable ethical opinion was obtained from the East of Scotland Research Ethics Committee (EoSREC) and granted to HIC Services for the curation and linkage of datasets such as these (reference: 14/ES/0015).

## **RESULTS**

An examination of the study population revealed that there was a higher proportion of males (73%, n=2668) than females (27%, n=996). **Figure 1** shows the distribution of age and deprivation status in the study population compared with the general population of Scotland.

[Insert Figure 1 around here]

**Figure 1a** shows that there was a higher proportion of those aged 30-49 years in the study cohort compared with the general population of Scotland. Consequently, there were lower proportions of those aged 20-29 years and 60+ years. **Figure 1b** shows that there was a higher proportion of deprived (quintiles 1-2) individuals and a lower proportion of affluent (quintiles 3-5) individuals than would be found in the general population.

A breakdown of the numbers in each group having attended the ED during the 12-month observation period is shown in **Figure 2**. This includes attendance by patients with chronic, painful conditions (as defined by analgesic prescribing) and those with chronic pain attending specifically for the treatment of CMP (identified by attendance code).

[Insert Figure 2 around here]

**Figure 2** shows that, of the 368 participants identified as having chronic pain, 68.5% (n=252) had attended the ED for any reason on at least one occasion during the observation period, and 32.3% (n=119) had attended for CMP management. **Figure 3** shows the proportion of those with and without chronic pain who attended the ED for any reason on at least one occasion during the observation period, and it describes presenting complaint in those with chronic pain who attended the ED.

[Insert Figure 3 around here]

**Figure 3a** shows that, compared with those with no pain, a significantly higher proportion of those with chronic pain attended the ED for any reason on at least one occasion during the observation period ( $\chi^2(1)=219$ ;  $p<0.001$ ;  $\omega=0.244$ ). **Figure 3b** shows that almost half of those with chronic pain who attended the ED attended for CMP management. A further 28 participants with chronic pain attended the cardiovascular and gastrointestinal specialties: these participants could have been seeking treatment for chronic pain but there was insufficient clinical information contained within the dataset to determine specific reasons for attendance. **Figure 4** shows analgesic prescribing characteristics in those with chronic pain who did and did not attend the ED during the observation period.

[Insert Figure 4 around here]

**Figure 4** shows that around a quarter of those in receipt of prescribed analgesics were prescribed opioids, and there was little difference in this pattern between groups. There was no group difference in mean oral morphine-equivalent daily dose (oMEDD) between those that attended and did not attend the ED. Analgesic prescriptions were issued for a mean duration of around 6 months during the observation period, and there was little difference between groups. It should be noted that this figure refers to the issue of analgesic prescriptions during the 12-month observation period, and that data were not available to facilitate estimates of the length of time in receipt of analgesic prescriptions outside of the observation period.

#### ***Risk of emergency department attendance for chronic musculoskeletal pain management***

**Table 1** shows the sociodemographic characteristics, analgesic treatment characteristics and medical and psychiatric morbidities associated with risk of attendance at the ED for CMP management. Only 3.0% (n=7) of participants were diagnosed with malignant disease and 1.3% (n=3) had their pain problems treated in a specialist pain service. Due to low numbers, these variables were not included in the analyses.

[Insert Table 1 around here]

**Table 1** shows that a significantly higher proportion of those that attended for the treatment of CMP was male and relatively socioeconomically affluent. In consequence, the remainder of the analyses were adjusted for gender and deprivation status. The adjusted odds ratios show that being prescribed strong opioids, transitioning from non-opioid to opioid analgesics and recent analgesic dose increases were each independently protective of ED attendance for CMP management. Conversely, recent analgesic dose decreases and

transitioning from opioid to non-opioid analgesics were predictive of ED attendance in this group. Furthermore, there were no associations with medical morbidity, but being in receipt of prescribed antidepressants (specifically tricyclics), benzodiazepines and hypnotics for the treatment of psychiatric disorders were independently protective of ED attendance for CMP management.

### ***Relative cost of emergency department treatment for chronic pain management***

All ED attendances (n=1,219) were included in calculating the cost of ED treatment for CMP relative to that of other clinically-significant morbidities. This included participants with chronic pain (n=252) and without chronic pain (n=967). Findings are shown in **Table 2**.

[Insert Table 2 around here]

**Table 2** shows that more patients attended the ED for the treatment of CMP than for any other clinically-significant medical condition, and that this was one of the most expensive conditions overall to treat, second only to that of cardiovascular disease. Based on a Scottish population estimate of 5.42 million and the figures in the present study, more than 174,000 patients are likely to seek treatment for CMP management across Scotland in any 12-month period, with ED costs for the treatment of this condition likely to amount to around £26 million (~\$33 million).

## **DISCUSSION**

More than two thirds of those identified with CP attended the ED for any problem during the observation period, with almost a half of these attending for CMP management. A higher proportion of those that attended with CMP was male and relatively

socioeconomically affluent. Being in receipt of prescribed strong opioid analgesics, transitioning from non-opioid to opioid analgesics and recent analgesic dose increases were each independently protective of ED attendance for CMP management. Conversely, recent analgesic dose decreases and transitioning from opioid to non-opioid analgesics were predictive of ED attendance. Being in receipt of prescribed tricyclic antidepressants, benzodiazepines and hypnotics were independently protective of ED attendance for CMP management. More patients attended the ED with CMP than with any other medical condition, and this was one of the most expensive conditions overall to treat. Projected estimates suggest that almost 175,000 patients are likely to seek treatment for CMP across Scotland (population = 5.42M million) in any 12-month period, with ED costs for the treatment of this condition likely to amount to around £26 million (~\$33 million).

As a result of data collection processes across Scottish EDs, it is not currently possible to identify all attendances for CP management. As discussed, the present study used the best available surrogate indicator – painful musculoskeletal conditions (excluding injury); however, this fails to encompass important conditions, such as abdominal and pelvic pain, and some presentations may have been for relatively short-term problems (although in people already identified with CP). In an examination of all loci of pain in 5,279 patients with CP in the UK [913], 7443 specific sites of pain were reported. Most loci were suggestive of musculoskeletal pain (89%); however, there was also a substantial prevalence of abdominal (8%) and pelvic (3%) pain. In consequence, the prevalence and costs reported in this article are likely to be an underestimate of the true burden of CP placed upon ED resources.

~~Whilst CP is more prevalent in females than males [8,17,26,48,55,57], the present study found that male gender was a risk factor for ED attendance for CMP. A higher prevalence of chronic pain is often reported in females [12,27,37,66,73,75], and females are associated with more frequent ED attendance [5,55]. However, similar to the findings of a~~



previous study examining all-cause ED attendance [2], the present study found that male gender was a significant risk factor for ED attendance for unmanageable pain. Men are reported to be twice as likely as women to have inadequate health literacy [76]. Furthermore, men have been shown to be less likely to seek medical assistance from general practitioners [1,23,35,78], pharmacists [56] and pain services specifically [10,22,45] when they are ill. It may be the case that men are relatively reluctant to seek medical assistance prior to reaching crisis stage; indeed, Juel and Christensen [43] suggested a link between men's lower use of primary care and higher use of hospital services in their analysis of 35.8 million general practitioner attendances and 1.2 million hospitalisations in Denmark during 2005. Our data, however, do not allow a definitive explanation for this finding. All-cause ED attendance is reported to be most common in socioeconomically deprived individuals [6,31,49]. However, similar to the findings of Poulin and colleagues [46], the present study found that socioeconomic affluence was a risk factor for ED attendance specifically for CMP management. A higher proportion of males and affluent individuals may be more likely to be in full-time employment thus finding it harder to attend a GP practice during working hours; indeed, Zhou and colleagues [64] found that the inability to get to an in-hours GP appointment was associated with higher use of out-of-hours healthcare services. ED attendance for any complaint is reported to be most common in socioeconomically deprived individuals [9,46,67], and these individuals have been shown to demonstrate a preference for hospital treatment compared with primary care [44]. However, similar to the findings of Poulin and colleagues [64], the present study found that relative socioeconomic affluence was a risk factor for ED attendance specifically for acute exacerbation of chronic pain. Joynt and colleagues [42] found that patients from the highest socioeconomic quartile were more likely to receive opioid analgesics on presentation at EDs compared with those from the lowest quartile, and it may be that a proportion of those with low socioeconomic status avoid the ED

based on previous experience of not having received immediate pain relief. However, it is impossible to interpret this finding without further research.

Whilst prescription opioids are associated with increased overdose risk [4217,5674,6080] and high doses are associated with ED attendance for alcohol- and drug-related problems [47], the present study found that opioid (compared with non-opioid) analgesics and higher doses were protective of ED attendance for CMP management. Furthermore, recent opioid analgesic dose reductions and transitioning from opioid to non-opioid analgesics were risk factors for ED presentation with CMP. An understanding of the potential adverse effects of opioid tapering in patients with CP is yet to be achieved, as highlighted in a recent systematic review of the topic [3550]. However, one study [3651] found that, following analgesic opioid tapering and eventual discontinuation in patients with CNCP, 49% of their 494 participants experienced an opioid-related hospitalisation or ED attendance as a result of overdose or other problems associated with problematic use. As with our present study, these findings echo a recent Food and Drug Administration (FDA) safety announcement concerning potential ‘serious harm’ associated with rapid tapering or discontinuation of opioid analgesics, such as withdrawal symptoms, uncontrolled pain, psychological distress and suicide [2232]. Whilst there are potential risks associated with opioid prescribing, the findings of this study suggest that adequate pain management may help to stabilise pain problems in patients with CP and reduce the need for ED intervention, and that opioid tapering or discontinuation should not be implemented in the absence of an alternative pain management plan and careful monitoring of potential adverse effects.

Being in receipt of prescribed tricyclic antidepressants (but not selective serotonin reuptake inhibitors (SSRIs)), benzodiazepines and/or hypnotics for the management of psychiatric disorders was independently protective of ED attendance for CMP management. Tricyclic antidepressants (TCAs) and serotonin noradrenaline reuptake inhibitors (SNRIs) are

commonly used in the treatment of chronic neuropathic pain

[43,4318,4929,2030,3954,4765]; whereas, SSRIs are ineffective in CP management [43,4015,4929,2030]. Furthermore, a recent systematic review of randomized control trials [3348] highlighted the effectiveness of TCAs in treating insomnia. Insomnia is shown to exacerbate pain problems [4828,3247,50], and the potential therapeutic effect of TCAs on insomnia may account for the protective effect on ED attendances for CMP in a portion of patients with CP.

Clinical insomnia and anxiety disorders are more prevalent in individuals with CP than in pain-free controls [4260,5169,5877]. Pain is now widely understood as a multidimensional construct featuring a strong emotional component in addition to sensory experiences [2940], and pain problems are shown to be exacerbated by both anxiety [2536,6383] and insomnia [4828,3247,5068]. Our findings that benzodiazepine or hypnotic use reduced ED attendance for CMP may relate to the central effects of these agents, with a possible decrease in anxiety (or insomnia), although these agents are recommended only for short term use. Furthermore, there are serious risks associated with the concomitant use of opioids and central nervous system depressants, which can ultimately result in premature mortality due to respiratory depression [4419,3041,4057,4361]. There is a need for further studies examining non-pharmaceutical interventions for the treatment of anxiety disorders and insomnia in patients with CMP to ensure safe and effective clinical practice.

To the authors' knowledge, this is the first study to examine the burden that CMP places upon EDs. CMP was the second most resource-intensive medical condition to treat in the ED, despite previous findings suggesting that CP is not most effectively managed by emergency services [24,5270,6181,6282]. Indeed, this finding further supports the proposal that effective community-based pain management could alleviate some of the pressure placed upon EDs, and that there is a need to identify and implement treatments that are at least as

effective as analgesic pain management for patients who require opioid tapering. The projected national cost estimates presented here require validation in national studies, and further research is required to understand patients' motives for, and expectations of, presentation at EDs with CMP. Only through the proposed further research can cost-effective pain management policy be developed which could deliver effective treatment to those with CMP, thereby improving overall quality of life.

### ***Limitations***

The study cohort was characterised by a relatively high proportion of males and a lower proportion of those aged 60+ years compared with the Scottish population as a whole, and this may have resulted in an underestimation of pain prevalence and treatment costs [4625]. Conversely, the relatively high proportion of socioeconomically deprived individuals may have resulted in an overestimation of these figures due to the poorer health associated with these socioeconomic groups [4520]. A key limitation of the present study is that the identification of participants with CP was based on community-dispensed analgesic prescribing for at least 3 consecutive months within the observation period; ~~and this,~~ therefore, this did not include individuals who were treated only with non-pharmaceutical interventions or over-the-counter (OTC) medication, and it may have resulted in the exclusion of some individuals who had been hospitalised during the observation period or had migrated to the area relatively recently. In consequence, the findings of the present study are likely to be an underestimation of the numbers attending the ED with CP and the total cost of treatment. The principal limitation in estimating the burden of CP on ED resources is that, due to the nature of ED data coding, it is not currently possible to identify all attendances for CP. Attendance for CMP was considered the most appropriate surrogate indicator. A further limitation is that the Scottish Morbidity Register (SMR) 00 (outpatient

clinic activity) is known to provide underestimates of the number of patients attending specialist pain services, which may account for the insufficient numbers in the present study to enable statistical testing. It should be noted that patients may have their CP treated in other specialist services (such as orthopaedics or neurology) but that administrative datasets do not provide sufficient clinical information to identify these patients. Finally, psychometric assessment of the process of assigning BNF codes (indicating intention to treat) in the prescribing dataset could strengthen research using these data.

## ***Conclusions***

All-cause ED attendance was significantly higher in those with CP compared with those with no evident pain. More patients attended the ED for the treatment of CMP than for any other medical condition, and this was one of the most expensive conditions to treat, second only to cardiovascular disease. We have identified some sociodemographic and treatment-related factors associated with the rates of attendance that need to be considered with circumspection. There is a need to identify effective, community-based, non-pharmacological interventions to ensure safe treatment practices for patients with CMP and to help to reduce the need for ED interventions in the management of this chronic condition. Further research is needed to understand the factors that drive treatment-seeking behaviour, such as ED attendance, for CMP management.

## **ACKNOWLEDGEMENTS**

There are no financial or other acknowledgements to be made. The authors have no conflicts of interest to disclose.

## **DATA SHARING STATEMENT**

In accordance with the information governance policies of the data gatekeepers, the data used in the present analyses are not available for sharing.

## REFERENCES

[1] Addis ME, Mahalik JR. Men, masculinity, and the contexts of help seeking. *Am Psychol* 2003;58:1:5–14.

[2] Anson O, Carmel S, Levin M. Gender differences in the utilization of emergency department services. *Women Health* 1991;17(2):91-104.

[43] Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol* 2010;17:1113–1123.

[24] Baker K. Chronic pain syndromes in the emergency department: identifying guidelines for management. *Emerg Med Australas* 2005;17(1):57–64.

[5] Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. *Fam Pract* 2000;49(2):147–152.

[36] Bernard AM, Wright SW. Chronic pain in the ED. *Am J Emerg Med* 2004;22(6):444–447.

[47] Braden JB, Russo J, Fan M-Y, Edlund MJ, Martin BC, De Vries A, Sullivan MD.

Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med 2010;170(16):1425-1432.

[58] Chen E, Tsoy D, Upadhye S, Chan TM. The Acute Care of Chronic Pain Study:

perceptions of acute care providers on chronic pain, a social media-based Investigation.

Cureus 2018;10(3):e2399.

[69] Cookson R, Propper C, Asaria M, Raine R. Socio-economic inequalities in health care in

England. Fisc Stud 2016;37(3–4):371–403.

[\[10\] Cornally N, McCarthy G. Chronic pain: the help-seeking behavior, attitudes, and beliefs](#)

[of older adults living in the community. Pain Manag Nurs 2011;12:206–17.](#)

[711] Crawford K, Morphet J, Jones T, Innes K, Griffiths D, Williams A. Initiatives to reduce

overcrowding and access block in Australian emergency departments: a literature review.

Collegian 2014;21(4):359-366.

[812] Dao TT, LeResche L. Gender differences in pain. J Orofac Pain 2000;14:169–184.

[913] Davies HTO, Crombie IK, Macrae WA. Where does it hurt? Describing the body

locations of chronic pain. Eur J of Pain 1998;2:69-80.

[14] Desai N, Shah P. High burden of hospital resource utilization in patients with hidradenitis suppurativa in England: a retrospective cohort study using hospital episode statistics. Br J Dermatol 2017;176(4):1048-1055.

[4015] Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012;52:6-17.

[4416] Du S, Yuan C, Xiao X, Chu J, Qiu Y, Qian H. Self-management programs for chronic musculoskeletal pain conditions: a systematic review and meta-analysis. Patient Educ Couns 2011;85(3):e299-310.

[4217] Dunn KN, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152(2):85-92.

[4318] Dworkin RH, O'Connor B, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237–251.

[4419] Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014;348:g445.



[4520] Elliott AM, Smith BH, K Penny KI, Smith WC, Chambers WA. The Epidemiology of Chronic Pain in the Community. Lancet 1999;354(9186):1248-52.

[21] Elliott J, Jacques RM, Kruger J, Campbell MJ, Amiel SA, Mansell P, Speight J, Brennan A, Heller SR. Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes. Diabet Med 2014;31(7):847-853.

[22] Eriksen J, Sjogren P, Ekholm O, Rasmussen NK. Health care utilisation among individuals reporting long-term pain: an epidemiological study based on Danish National Health Surveys. Eur J Pain 2004;8:517–23.

[23] European Commission. The state of men’s health in Europe—extended report. Brussels: European Union, 2011.

[24] Farmer AJ, Brockbank KJ, Keech ML, England EJ, Deakin CS. Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England. Diabet Med 2012;29(11):1447-1450.

[4625] Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open 2016;6:e010364.

[26] Fielding S, Porteous T, Ferguson J, Maskrey V, Blyth A, Paudyal V, Barton G, Holland R, Bond CM, Watson MC. Estimating the burden of minor ailment consultations in general

[practices and emergency departments through retrospective review of routine data in North East Scotland. Fam Pract 2015;32\(2\):165-172.](#)

[~~17~~[27](#)] Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL, 3<sup>rd</sup>. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain 2009;10:447–485.

[~~18~~[28](#)] Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. J Pain 2013;14(12):1539–1552.

[~~19~~[29](#)] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162–173.

[~~20~~[30](#)] Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573–581.

[~~21~~[31](#)] Flowerdew L, Brown R, Russ S, Vincent C, Woloshynowych M. Teams under pressure in the emergency department: an interview study. Emerg Med J 2012;29:e2.

[~~22~~[32](#)] Food and Drug Administration (2019). FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering FDA Drug Safety Communication.

<https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes>

[2333] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392(10159): 1789–1858.

[2434] Graham CA. Emergency care systems: increasing pressures but little sustainability. *Eur J Emerg Med* 2017;24(3):157.

[35] Green CA, Pope CR. Gender, psychosocial factors and the use of medical services: a longitudinal analysis. *Soc Sci Med* 1999;48:1363–72.

[2536] Gureje O. Comorbidity of pain and anxiety disorders. *Curr Psychiatry Rep* 2008;10:318–322.

[2637] Hardt J, Jacobsen C, Goldberg J, Nickel R, Buchwald D. Prevalence of chronic pain in a representative sample in the United States. *Pain Med* 2008;9:803–812.

[2738] He J, Hou X-Y, Toloo S, Patrick JR, FitzGerald G. Demand for hospital emergency departments: a conceptual understanding. *World J Emerg Med* 2011; 2(4): 253–261.

[2839] Hsia RY, Nath JB, Baker LC. California emergency department visit rates for medical conditions increased while visit rates for injuries fell, 2005–11. *Health Aff* 2015;34:621–6.

[2940] IASP. Task force on taxonomy of the international association for the study of pain.

In: Merskey H, Bogduk N, editors. Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. Seattle, Wash, USA: IASP Press, 1994.

[3041] Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. *Am J Prev Med* 2015;49(4):493-501.

[42] Joynt M, Train MK, Robbins BW, Halterman JS, Caiola E, Fortuna RJ. The impact of neighborhood socioeconomic status and race on the prescribing of opioids in emergency departments throughout the United States. *J Gen Intern Med* 2013;28(12):1604-10.

[43] Juel K, Christensen K. Are men seeking medical advice too late? Contacts to general practitioners and hospital admissions in Denmark 2005. *J Public Health* 2008;30(1):111-113.

[44] Kangovi S, Barg FK, Carter T, Long JA, Shannon R, Grande D. Understanding why patients of low socioeconomic status prefer hospitals over ambulatory care. *Health Aff (Millwood)* 2013;32(7):1196-203.

[45] Kaur S, Stechuchak KM, Coffman CJ, Allen KD, Bastian LA. Gender differences in health care utilization among veterans with chronic pain. *J Gen Intern Med* 2007;22:228-33.

[3446] Khan Y, Glazier RH, Moineddin R, Schull KN. A population-based study of the association between socioeconomic status and emergency department utilization in Ontario, Canada. *Acad Emerg Med* 2011;18(8):836-43.

[3247] Kundermann B, Krieg JC, Schreiber W, Lautenbacher S. The effects of sleep deprivation on pain. *Pain Res Manag* 2004;9(1):25-32.

[3348] Liu Y, Xu X, Dong M, Jia S, Wei Y. Treatment of insomnia with tricyclic antidepressants: a meta-analysis of polysomnographic randomized controlled trials. *Sleep Med* 2017;34:126-133.

[3449] Lowthian JA, Curtis AJ, Cameron PA, et al Systematic review of trends in emergency department attendances: an Australian perspective. *Emerg Med J* 2011;28:373-377.

[3550] Mackey K, Anderson J, Bourne D, Chen E, Peterson K. Evidence Brief: Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-199; 2019.

[3651] Mark TL, Parish W. Opioid Medication Discontinuation and risk of adverse opioid-related health care events. *J Subst Abuse Treat* 2019;103:58-63.

[3752] Mason S, Mountain G, Turner J, Arain M, Revue E, Weber EJ. Innovations to reduce demand and crowding in emergency care; a review study. *Scand J Trauma Resusc Emerg Med* 2014;22:55.

[3853] Massimi A, De Vito C, Brufola I, Corsaro A, Marzuillo C, Migliara G, Rega ML, Ricciardi W, Villari P, Damiani G. Are community-based nurse-led self-management support interventions effective in chronic patients? Results of a systematic review and meta-analysis. PLoS One 2017;12(3):e0173617.

[3954] Micó JA, Ardid D, Berrocoso E, Eschalier A (2006) Antidepressants and pain. Trends in Pharmacol Sci 2006;27(7):348-354.

[55] Milani SA, Crooke H, Cottler LB, Striley CW. (2016). Sex differences in frequent ED use among those with multimorbid chronic diseases. Am J Emerg Med 2016;34(11):2127–2131.

[56] National Pharmacy Association (2012): [https://www.npa.co.uk/Documents/Docstore/AYP2012/AN\\_INTERIM\\_REVIEW\\_BY\\_THE\\_NPA\\_OF\\_MEN%E2%80%99S\\_UPTAKE\\_OF\\_PHARMACY\\_SERVICES\\_NOVEMBER%202012\\_.pdf](https://www.npa.co.uk/Documents/Docstore/AYP2012/AN_INTERIM_REVIEW_BY_THE_NPA_OF_MEN%E2%80%99S_UPTAKE_OF_PHARMACY_SERVICES_NOVEMBER%202012_.pdf).

[4057] Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction 2007;102(4):616-622.

[4458] Palmer KT, Harris EC, Linaker C, Barker M, Lawrence W, Cooper C, Coggon D. Effectiveness of community- and workplace-based interventions to manage musculoskeletal-related sickness absence and job loss: a systematic review. Rheumatology 2012;51(2):230-42.

[59] [Parkinson K, Newbury-Birch D, Phillipson A, Hindmarch P, Kaner E, Stamp E, Vale L,](#)

[Wright J, Connolly J. Prevalence of alcohol related attendance at an inner city emergency](#)

[department and its impact: a dual prospective and retrospective cohort study. Emerg Med J](#)

[2016;33\(3\):187-193.](#)

[4260] Pereira FG, França MH, Paiva MCA, Andrade LH, Viana MC. Prevalence and clinical profile of chronic pain and its association with mental disorders. Rev Saude Publica 2017;51:96.

[4361] Pergolizzi JV, LeQuang JA. Reappraising the use of benzodiazepines in chronic pain patients. Postgrad Med 2020;6:1-3.

[4462] Portenoy RK, Bennett DS, Rauck R, Simon S, Taylor D, Brennan M, Shoemaker S. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7(8):583-91.

[4563] Potier T, Tims E, Kilbride C, Rantell K. Evaluation of an evidence based quality improvement innovation for patients with musculoskeletal low back pain in an accident and emergency setting. BMJ Qual Improv Rep 2015;4(1):u205903.w2411.

[4664] Poulin PA, Nelli J, Tremblay S, Small R, Caluyong MB, Freeman J, Romanow H, Stokes Y, Carpino T, Carson A, Shergill Y, Stiell IG, Taljaard M, Nathan H, Smyth CE. Chronic pain in the emergency department: a pilot mixed-methods cross-sectional study examining patient characteristics and reasons for presentations. Pain Res Manag 2016;2016:3092391.

[4765] Rodieux F, Piguet V, Berney P, Desmeules J, Besson M. Pharmacogenetics and analgesic effects of antidepressants in chronic pain management. *Per Med* 2015;12(2):163-175.

[4866] Rollman GB, Lautenbacher S. Sex differences in musculoskeletal pain. *Clin J Pain* 2001;17:20–24.

[4967] Shah SM, Cook DG. Socio-economic determinants of casualty and NHS Direct use. *J Public Health (Oxf)* 2008;30(1):75–81.

[5068] Tang NKY. Insomnia co-occurring with chronic pain: clinical features, interaction, assessments and possible interventions. *Rev Pain* 2008;2(1):2–7.

[5169] Tang NKY, Wright KJ, Salkovskis PM. Prevalence and correlates of clinical insomnia co-occurring with chronic back pain. *J Sleep Res* 2007;16:85–95.

[5270] Todd KH, Cowan P, Kelly N, Homel P. Chronic or recurrent pain in the emergency department: national telephone survey of patient experience. *West J Emerg Med* 2010;11(5):408–415.

[5371] Todd KH, Ducharme J, Choiniere M, Johnson C, Crandall C, Puntillo K. Pain and pain-related functional interference among discharged emergency department patients. *Ann Emerg Med* 2004;44(4):S86.



[5472] United States Bone and Joint Initiative. Prevalence, Societal and Economic Cost. Third edition. Illinois: The Burden of Musculoskeletal Diseases in the United States; 2016. <http://www.boneandjointburden.org>

[5573] Unruh AM. Gender variations in clinical pain experience. Pain 1996;65:123–167.

[5674] Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies — tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063-2066.

[5775] Von Korff M, Dworkin SF, Le Resche L, Kruger A. An epidemiologic comparison of pain complaints. Pain 1988;32:173–183.

[76] von Wagner C, Knight K, Steptoe A, Wardle J. Functional health literacy and health-promoting behaviour in a national sample of British adults. J Epidemiol Commun H 2007;61:1086-1090.

[5877] Vun E, Turner S, Sareen J, Mota N, Afifi TO, El-Gabalawy R. Prevalence of comorbid chronic pain and mental health conditions in Canadian Armed Forces active personnel: analysis of a cross-sectional survey. CMAJ Open 2018;6(4):E528–E536.

[78] Wang Y, Hunt K, Nazareth I, Freemantle N, Petersen I. Do men consult less than women? An analysis of routinely collected UK general practice data. BMJ Open 2013;3:e003320.

[5979] Weaver RG, Manns BJ, Tonelli M, Sanmartin C, Campbell DJ, Ronksley PE, Lewanczuk R, Braun TC, Hennessy D, Hemmelgarn BR. Access to primary care and other health care use among western Canadians with chronic conditions: a population-based survey. CMAJ Open 2014;2(1):E27–E34.

[6080] Wilder C, Miller SC, Tiffany E, Winhusen T, Winstanley EL, Stein MD. Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain. J Addic Dis 2016;35(1):42-51.

[6481] Wilsey BL, Fishman SM, Tsodikov A, Ogden C, Symreng I, Ernst A. Psychological comorbidities predicting prescription opioid abuse among patients in chronic pain presenting to the emergency department. Pain Med 2008;9(8):1107–1117.

[6282] Wilsey BL, Fishman SM, Crandall M, Casamalhuapa C, Bertakis KD. A qualitative study of the barriers to chronic pain management in the ED. Am J Emerg Med 2008;26(3):255–263.

[6383] Woo AK. Depression and anxiety in pain. Rev Pain 2010;4(1):8–12.

~~[64] Zhou Y, Abel G, Warren F, Roland M, Campbell J, Lyratzopoulos G. Do difficulties in accessing in-hours primary care predict higher use of out-of-hours GP services? Evidence from an English National Patient Survey. Emerg Med J 2015;32(5):373-8.~~

## Figure legends

**Figure 1:** a. Distribution of age in the study cohort (percentages) compared with the distribution in the general Scottish population; and b. distribution of Scottish Index of Multiple Deprivation (SIMD) quintiles in the study population compared with the equal distribution (denoted by a horizontal line) found in the general population

Note: Scottish population age group data were obtained from the Office for National Statistics

(<https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/datasets/tablea26principalprojectionscotlandpopulationinagegroups>)

**Figure 2:** Breakdown of cohort by presence or absence of chronic pain and attendance at emergency departments

**Figure 3:** a. Proportions with chronic pain and no pain attending the emergency department for any reason on at least one occasion during the observation period; and b. presenting complaint in those with chronic pain who attended the emergency department

**Figure 4:** Analgesic prescribing characteristics in those with chronic pain who did and did not attend the emergency department during the observation period (a. percentage of participants in receipt of prescribed opioid analgesics; b. mean oral morphine-equivalent daily dose (mg) per patient over the 12-month observation period of those who were in receipt of prescribed opioid analgesics; c. mean months duration in receipt of any analgesic prescriptions during the observation period)

Summary

Emergency department attendance was higher in those with than without chronic pain. Risk factors for attendance suggest a need to apply more effective non-pharmacological treatments.

Figure 1




Figure 2




Figure 3





Figure 4





**Table 1:** Sociodemographic characteristics, analgesic treatment characteristics and psychiatric morbidity in those with chronic pain who attended the emergency department for the treatment of CMP in 2014 (n=119) compared with those with chronic pain who did not attend the emergency department (n=116)

Predictor	Reference	OR	OR <sup>adj</sup>	95% CI
<b><i>Sociodemographic characteristics</i></b>				
Male	Female	2.21	-----	0.26-3.89
Age	Each 1-year increase	0.99	-----	0.97-1.01
Socioeconomically affluent	Relatively deprived	2.06	-----	1.21-3.51
Rural habitation	Urban habitation	1.76	-----	0.94-3.27
<b><i>Analgesic treatment characteristics</i></b>				
Opioid analgesics	Non-opioid analgesic	0.78	0.77	0.38-1.55
Strong opioids	Weak opioids	0.18	0.21	0.05-0.89
Opioid to non-opioid	No change in class	5.39	5.08	1.42-18.16
Non-opioid to opioid	No change in class	0.23	0.25	0.07-0.94
Increase in analgesic dose	No change in dose	0.25	0.24	0.11-0.53
Decrease in analgesic dose	No change in dose	4.50	4.55	1.75-11.83
<b><i>Treatment for medical morbidity</i></b>				
Gastrointestinal (GI) disorders	No GI disorders	0.62	0.68	0.35-1.34
Cardiovascular (CV) disease	No CV disease	0.86	1.67	0.85-3.28
Respiratory disorders	No respiratory disorders	0.74	0.86	0.45-1.61
Endocrine disorders	No endocrine disorders	0.58	0.66	0.34-1.26
<b><i>Treatment for psychiatric morbidity</i></b>				
Opioid agonist therapy *	No mental illness **	1.36	1.64	0.95-2.85
Antidepressants	No mental illness **	0.39	0.54	0.29-0.99

<i>Tricyclic treatment †</i>	<i>SSRI treatment</i>	0.10	0.10	0.04-0.25
Benzodiazepines ‡	No mental illness **	0.34	0.46	0.21-0.98
Hypnotics	No mental illness **	0.34	0.45	0.20-1.00
Antipsychotics	No mental illness **	0.26	0.36	0.08-1.62

OR<sup>adj</sup> shows ORs adjusted for gender and deprivation status

\* All of these participants were treated with methadone hydrochloride

† All participants that were prescribed antidepressant medication were in receipt of either selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs) – no participants were in receipt of monoamine oxidase inhibitors (MAOIs) or other antidepressant medication

‡ All sedatives were included; however, all of these participants were prescribed benzodiazepines, almost exclusively diazepam

\*\* No psychotropic prescribing or attendance at specialist psychiatric services during 2014

**Table 2:** Cost of emergency department treatment for clinically-significant medical conditions in the study cohort and estimated national cost based on these figures and a Scottish population estimate of 5.42 million


Medical condition	Study cohort		Scottish population	
	(N=3,700)		(N=5.42 million)	
	n	£cost (\$)	N	£cost (\$)
Cardiovascular disease	100	20,410 (26,168)	146,340	29.87m (38.30m)
Chronic musculoskeletal pain	119	17,680 (22,668)	174,524	25.93m (33.24m)
Respiratory disease	45	12,740 (16,334)	66,124	18.72m (24.00m)
Gastrointestinal disorders	62	12,090 (15,501)	91,056	17.76m (22.77m)
Endocrine/metabolic disorders	25	6,110 (7,834)	36,856	9.01m (11.55m)
Substance use disorder	15	2,080 (2,667)	22,222	3.08m (3.95m)
Psychiatric disorders	14	1,950 (2,500)	20,596	2.87m (3.68m)



[Click here to access/download](#)

**Supplementary Materials: figures, tables**  
Supplementary digital content.docx





[Click here to access/download](#)

**Copyright Transfer Agreement--REQUIRED from ALL  
authors of submission at revision stage**  
PAIN\_Copyright\_Transfer\_Form [CH].pdf





[Click here to access/download](#)

**Copyright Transfer Agreement--REQUIRED from ALL  
authors of submission at revision stage**  
PAIN\_Copyright\_Transfer\_Form [BHS].pdf





[Click here to access/download](#)

**Copyright Transfer Agreement--REQUIRED from ALL  
authors of submission at revision stage**  
PAIN\_Copyright\_Transfer\_Form [LC].pdf





[Click here to access/download](#)

**ICMJE Conflict of Interest Form--REQUIRED from ALL  
authors of submission at revision stage**

Conflict of Interest [CH].pdf







[Click here to access/download](#)

**ICMJE Conflict of Interest Form--REQUIRED from ALL  
authors of submission at revision stage  
Conflict of Interest [BHS].pdf**





[Click here to access/download](#)

**ICMJE Conflict of Interest Form--REQUIRED from ALL  
authors of submission at revision stage**  
Conflict of Interest [LC].pdf

